reports
CREDIT AGRICOLE NORD DE FRANCE : AVIS DE MISE A DISPOSITION DU BILAN S...
CREDIT AGRICOLE NORD DE FRANCE : AVIS DE MISE A DISPOSITION DU BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE Lille, le 02 juillet 2025 COMMUNIQUE AVIS DE MISE A DISPOSITION DU BILAN SEMESTRIEL 2025 DU CONTRAT DE LIQUIDITE DU CREDIT AGRICOLE NORD DE FRANCE La Caisse régionale du Credit Agricole Nord de France annonce avoir mis à disposition du public et déposé auprès de l’Autorité des Marchés Financiers son bilan semestriel du contrat de liquidité contracté avec Oddo Corporate Finance. Le bilan semestriel 2025 du contrat de liquidité peut être consulté sur le site de présentatio...
- Felix Fischer
- Haidje Rustau
- Jayanth Kandalam
- Si Yong Ng
- Tanvi Arora
- Trung Nguyen
Lucror Analytics - Morning Views Europe
In today's Morning Views publication we comment on developments of the following high yield issuers: Victoria, Vallourec, Omnia Technologies, Paprec Group, La Doria, Softbank Group, Maxeda, Mahle, Bombardier, Flora Food Group (formerly Upfield), Nexans, Assemblin, Air Baltic, Virgin Media O2, Nokia
Total number of shares and voting rights in Zealand Pharma as of June ...
Total number of shares and voting rights in Zealand Pharma as of June 30, 2025 Company announcement – No. 16 / 2025 Total number of shares and voting rights in Zealand Pharma as of June 30, 2025 Copenhagen, Denmark, June 30, 2025 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces, in accordance with section 32 of the Danish Capital Markets Act, the total number of shares and voting rights in the Company at the end of a calendar mo...
Vallourec Secures a Significant OCTG Order with Abu Dhabi National Oil...
Vallourec Secures a Significant OCTG Order with Abu Dhabi National Oil Company (ADNOC) Press Release VALLOUREC SECURES A SIGNIFICANT OCTG ORDER WITH ABU DHABI NATIONAL OIL COMPANY (ADNOC) Meudon (France), June 30, 2025 – Vallourec, a world leader in premium seamless tubular solutions, has secured a significant order from Abu Dhabi National Oil Company (ADNOC) for the supply of more than 30,000 tons of carbon steel tubulars and associated accessories featuring VAM® premium connections. This order is part of the ongoing Long-Term Agreement (LTA) for the supply of Oil Country Tubular Goods (...
VALLOUREC REMPORTE UNE IMPORTANTE COMMANDE OCTG AUPRÈS D’ABU DHABI NAT...
VALLOUREC REMPORTE UNE IMPORTANTE COMMANDE OCTG AUPRÈS D’ABU DHABI NATIONAL OIL COMPANY (ADNOC) Communiqué de presse VALLOUREC REMPORTE UNE IMPORTANTE COMMANDE OCTG AUPRÈS D’ABU DHABI NATIONAL OIL COMPANY (ADNOC) Meudon (France), 30 juin 2025 – Vallourec, un leader mondial des solutions tubulaires premium sans soudure, a remporté une importante commande auprès d’Abu Dhabi National Oil Company (ADNOC) pour la fourniture de plus de 30 000 tonnes de tubes en acier carbone et d’accessoires associés équipés de connexions premium VAM®. Cette commande s’inscrit dans le cadre de l'accord à long t...
- Jacob Mekhael
ADA amylin monotherapy highlights Zealand, Novo, Lilly
The American Diabetes Association (ADA) conference was held 20-23 June, 2025 and contained a number of highly anticipated updates in the obesity pipeline. We summarise the key amylin monotherapy datasets in this note including data from Zealand from petrelintide's phase 1b showing higher weight loss in females, Lilly's eloralintide full presentation, which shows that the higher doses which showed competitive weight loss and generated excitement following the abstract release also come with heada...
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Thomas Couvreur
- Jacob Mekhael
Zealand Pharma We think sell off is overdone, jury is still out on elo...
Following the release of phase 1 MAD results for eloralintide (Lilly, no coverage) showing 11.3% weight loss at 12 weeks, Zealand's stock has declined -18% over the last 5 days. While the results look competitive vs. Zealand's petrelintide at first glance, key details on dosing and GI side effects per treatment arm remain undisclosed. We note that, given their similar activity on both amylin and calcitonin receptors, cagrilintide's long term 68 week data de-risks petrelintide's development. This...
- Felix Fischer
- Jayanth Kandalam
- Si Yong Ng
- Jacob Mekhael
Zealand Pharma Dapiglutide phase 1b shows strong weight loss, plans to...
Zealand announced topline results from part 2 of the phase 1b multiple ascending dose (MAD) trial of dapiglutide (long-acting GLP-1/GLP-2 receptor dual agonist) in overweight/obese participants, which showed 11.4% (placebo adjusted) weight loss, coming in higher than semaglutide, and closer to tirzepatide at a similar timepoint in the phase 3 (STEP-1 and SURMOUNT-1) trials. By targeting GLP-2 on top of GLP-1, dapiglutide aims to address low grade inflammation on top of weight loss. As such, we b...
- Hilde Van Boxstael
- Jacob Mekhael
- Thomas Couvreur
- Wim Hoste
- Wim Lewi
Vallourec Secures a Large Octg Contract in Qatar
Vallourec Secures a Large Octg Contract in Qatar Press Release VALLOUREC SECURES A LARGE OCTG CONTRACT IN QATAR Meudon (France), June 19, 2025 – Vallourec, a world leader in premium seamless tubular solutions, has secured a large contract to supply Oil Country Tubular Goods (OCTG) for drilling operations in Qatar. This new contract represents over $50 million in potential revenue. The agreement includes the supply of carbon steel OCTG products with premium connections, to be delivered in 2026 to support Qatar’s increasing drilling activity both onshore and offshore. Vallourec has a his...
VALLOUREC REMPORTE UN CONTRAT IMPORTANT EN OCTG AU QATAR
VALLOUREC REMPORTE UN CONTRAT IMPORTANT EN OCTG AU QATAR Communiqué de presse VALLOUREC REMPORTE UN CONTRAT IMPORTANT EN OCTG AU QATAR Meudon (France), 19 juin 2025 – Vallourec, un leader mondial des solutions tubulaires premium sans soudure, a remporté un contrat important pour la fourniture de tubes OCTG destinés aux opérations de forage au Qatar. Ce nouveau contrat représente un chiffre d’affaires potentiel de plus de 50 millions de dollars. L’accord comprend la fourniture de produits OCTG en acier carbone avec connexions premium, qui seront livrés en 2026 pour accompagner l’in...
Zealand Pharma announces positive topline results from 28-week Phase 1...
Zealand Pharma announces positive topline results from 28-week Phase 1b trial with GLP-1/GLP-2 receptor dual agonist dapiglutide Company announcement – No. 15 / 2025 Zealand Pharma announces positive topline results from 28-week Phase 1b trial with GLP-1/GLP-2 receptor dual agonist dapiglutide Body weight reductions of a mean of 11.6% after 28 weeks with dapiglutide escalated up to 26 mg, with 95% of trial participants being male, a median baseline BMI of 28.5 kg/m2, and no lifestyle modificationsTreatment with dapiglutide was assessed to be safe and well-tolerated with gastrointestinal a...
Zealand Pharma increases its share capital as a result of the exercise...
Zealand Pharma increases its share capital as a result of the exercise of employee warrants Company announcement – No. 14 / 2025 Zealand Pharma increases its share capital as a result of the exercise of employee warrants Copenhagen, Denmark, June 6, 2025 – Zealand Pharma A/S (“Zealand Pharma”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, has by decision of the Board of Directors increased its share capital by a nominal amount of DKK 292,508 divided into 292,508 new shares with a nominal value ...
Vallourec Completes the Acquisition of Thermotite do Brasil
Vallourec Completes the Acquisition of Thermotite do Brasil VALLOUREC COMPLETES THE ACQUISITION OF THERMOTITE DO BRASIL Meudon (France), June 5, 2025 – Vallourec, a world leader in premium seamless tubular solutions, today announces the completion of the acquisition of Thermotite do Brasil from Mattr (MATR.TO), in accordance with the terms of the agreement announced on September 16, 2024. This operation supports Vallourec's premiumization strategy, with the integration of differentiated technological expertise in thermal insulation coatings for pipelines. With this integrated offering, V...
VALLOUREC FINALISE L’ACQUISITION DE THERMOTITE DO BRASIL
VALLOUREC FINALISE L’ACQUISITION DE THERMOTITE DO BRASIL VALLOUREC FINALISE L’ACQUISITION DE THERMOTITE DO BRASIL Meudon (France), le 5 juin 2025 – Vallourec, leader mondial des solutions tubulaires premium sans soudure, annonce aujourd’hui la finalisation de l’acquisition de la filiale Thermotite do Brasil auprès de Mattr (MATR.TO), conformément aux termes de l’accord annoncé le 16 septembre 2024. Cette opération s’inscrit dans la stratégie de montée en gamme de Vallourec, avec l’intégration d’une expertise technologique différenciante, dans le domaine des revêtements d’isolation thermi...
VALLOUREC OBTIENT LA QUALIFICATION DE SA SOLUTION DE STOCKAGE D’HYDROG...
VALLOUREC OBTIENT LA QUALIFICATION DE SA SOLUTION DE STOCKAGE D’HYDROGÈNE ET LANCE SA COMMERCIALISATION Communiqué de presse VALLOUREC OBTIENT LA QUALIFICATION DE SA SOLUTIONDE STOCKAGE D’HYDROGÈNE ET LANCE SA COMMERCIALISATION Meudon (France), le 5 juin 2025 – Vallourec, leader mondial des solutions tubulaires premium sans soudure, annonce la qualification officielle de Delphy, sa solution de stockage vertical d’hydrogène gazeux, par DNV. Première mondiale, Delphy permet de stocker de 1 à 100 tonnes d’hydrogène dans des conditions de sécurité maximale. Grâce à une faible emprise au ...
VALLOUREC OBTAINS THE QUALIFICATION OF ITS HYDROGEN STORAGE SOLUTION A...
VALLOUREC OBTAINS THE QUALIFICATION OF ITS HYDROGEN STORAGE SOLUTION AND LAUNCHES COMMERCIALIZATION Press Release VALLOUREC OBTAINS THE QUALIFICATION OF ITS HYDROGEN STORAGE SOLUTION AND LAUNCHES COMMERCIALIZATION Meudon (France), June 5, 2025 – Vallourec, a world leader in premium seamless tubular solutions, announces the official qualification of Delphy, its vertical gaseous hydrogen storage solution, by DNV. A world first, Delphy enables the storage of 1 to 100 tons of hydrogen under maximum safety conditions. Thanks to its minimal footprint, this vertical system - extending up to ...
- Jacob Mekhael
Zealand Pharma FIRST LOOK: Submits glepaglutide MAA to the EMA in shor...
Zealand announced the submission of a marketing authorization application (MAA) to the European Medicines Agency (EMA) for glepaglutide twice weekly (long-acting GLP-2 analog) in adults with short bowel syndrome (SBS). Looking ahead, we look forward to the initiation of the confirmatory phase 3 trial in the US, expected in 2H25. Beyond glepaglutide, which represents a small fraction of our SOTP, additional phase 1b data (higher dosing and longer treatment) for dapiglutide (long acting GLP-1/GLP-...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.